AI assistant
ENTROPY NEURODYNAMICS LIMITED — Capital/Financing Update 2021
Apr 14, 2021
64855_rns_2021-04-14_4bcbd31a-0057-4e54-a1a5-7e25b7cb9f17.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Market Announcement
==> picture [33 x 50] intentionally omitted <==
15 April 2021
==> picture [451 x 5] intentionally omitted <==
Exopharm Limited (ASX: EX1) – Trading Halt
Description
The securities of Exopharm Limited (‘EX1’) will be placed in trading halt at the request of EX1, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 20 April 2021 or when the announcement is released to the market.
Issued by
Daniel Nicholson
Adviser, Listings Compliance (Perth)
Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au
15 April 2021 ASX Limited
==> picture [595 x 81] intentionally omitted <==
15 April 2021
Mr Daniel Nicholson Adviser, Listings Compliance Australian Securities Exchange Level 40, Central Park 152-158 St Georges Terrace Perth WA 6000
By email: [email protected]
Dear Daniel,
REQUEST FOR TRADING HALT
Exopharm Limited (ASX: EX1) (“ Exopharm ” or the “ Company ”) requests, pursuant to Listing Rule 17.1, a trading halt of the Company’s securities effective immediately pending the release of an announcement relating to a capital raising.
The trading halt is requested until the earlier of the release of an announcement relating to Exopharm’s capital raising or prior to the opening of trading on Tuesday 20 April 2021.
The Company is not aware of any reason why the trading halt should not be granted.
Yours sincerely
==> picture [123 x 51] intentionally omitted <==
Elizabeth McGregor Company Secretary
EXOPHARM LIMITED ACN: 163 765 991 ASX:EX1 Address: Level 17, 31 Queen Street Melbourne 3000 Telephone: 03 9111 0026 Email: [email protected] Web: www.exopharm.com